A hitchhiker's guide to the Trojan Horse Method

Owing the presence of the Coulomb barrier at astrophysically relevant kinetic energies, it is very difficult, or sometimes impossible to measure astrophysical reaction rates in laboratory. This is why different indirect techniques are being used along with direct measurements. The THM is unique indirect technique allowing one measure astrophysical rearrangement reactions down to astrophysical relevant energies. The basic principle and a review of the main application of the Trojan Horse Method are presented. A step-by-step approach will be adopted in order to describe the features usually unknown to non-experts

Uniform electron gases

We show that the traditional concept of the uniform electron gas (UEG) --- a homogeneous system of finite density, consisting of an infinite number of electrons in an infinite volume --- is inadequate to model the UEGs that arise in finite systems. We argue that, in general, a UEG is characterized by at least two parameters, \textit{viz.} the usual one-electron density parameter $\rho$ and a new two-electron parameter $\eta$. We outline a systematic strategy to determine a new density functional $E(\rho,\eta)$ across the spectrum of possible $\rho$ and $\eta$ values.Comment: 8 pages, 2 figures, 5 table

Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience

Convection-enhanced delivery (CED) of highly stable PEGylated liposomes encapsulating chemotherapeutic drugs has previously been effective against malignant glioma xenografts. We have developed a novel, convectable non-PEGylated liposomal formulation that can be used to encapsulate both the topoisomerase I inhibitor topotecan (topoCED™) and paramagnetic gadodiamide (gadoCED™), providing an ideal basis for real-time monitoring of drug distribution. Tissue retention of topoCED following single CED administration was significantly improved relative to free topotecan. At a dose of 10 μg (0.5 mg/ml), topoCED had a half-life in brain of approximately 1 day and increased the area under the concentration–time curve (AUC) by 28-fold over free topotecan (153.8 vs. 5.5 μg day/g). The combination of topoCED and gadoCED was found to co-convect well in both naïve rat brain and malignant glioma xenografts (correlation coefficients 0.97–0.99). In a U87MG cell assay, the 50% inhibitory concentration (IC50) of topoCED was approximately 0.8 μM at 48 and 72 h; its concentration–time curves were similar to free topotecan and unaffected by gadoCED. In a U87MG intracranial rat xenograft model, a two-dose CED regimen of topoCED co-infused with gadoCED greatly increased median overall survival at dose levels of 0.5 mg/ml (29.5 days) and 1.0 mg/ml (33.0 days) vs. control (20.0 days; P < 0.0001 for both comparisons). TopoCED at higher concentrations (1.6 mg/ml) co-infused with gadoCED showed no evidence of histopathological changes attributable to either agent. The positive results of tissue pharmacokinetics, co-convection, cytotoxicity, efficacy, and lack of toxicity of topoCED in a clinically meaningful dose range, combined with an ideal matched-liposome paramagnetic agent, gadoCED, implicates further clinical applications of this therapy in the treatment of malignant glioma

Anti-angiogenic therapy for cancer: Current progress, unresolved questions and future directions

Tumours require a vascular supply to grow and can achieve this via the expression of pro-angiogenic growth factors, including members of the vascular endothelial growth factor (VEGF) family of ligands. Since one or more of the VEGF ligand family is overexpressed in most solid cancers, there was great optimism that inhibition of the VEGF pathway would represent an effective anti-angiogenic therapy for most tumour types. Encouragingly, VEGF pathway targeted drugs such as bevacizumab, sunitinib and aflibercept have shown activity in certain settings. However, inhibition of VEGF signalling is not effective in all cancers, prompting the need to further understand how the vasculature can be effectively targeted in tumours. Here we present a succinct review of the progress with VEGF-targeted therapy and the unresolved questions that exist in the field: including its use in different disease stages (metastatic, adjuvant, neoadjuvant), interactions with chemotherapy, duration and scheduling of therapy, potential predictive biomarkers and proposed mechanisms of resistance, including paradoxical effects such as enhanced tumour aggressiveness. In terms of future directions, we discuss the need to delineate further the complexities of tumour vascularisation if we are to develop more effective and personalised anti-angiogenic therapies. © 2014 The Author(s)

Change in structure between the I = 1/2 states in 181Tl and 177,179Au

The first accurate measurements of the α-decay branching ratio and half-life of the Iπ=1/2+ ground state in 181Tl have been made, along with the first determination of the magnetic moments and I=1/2 spin assignments of the ground states in 177,179Au. The results are discussed within the complementary systematics of the reduced α-decay widths and nuclear g factors of low-lying, Iπ=1/2+ states in the neutron-deficient lead region. The findings shed light on the unexpected hindrance of the 1/2+→1/2+, 181Tl→g177Aug α decay, which is explained by a mixing of π3s1/2 and π2d3/2 configurations in 177Aug, whilst 181Tlg remains a near-pure π3s1/2. This conclusion is inferred from the g factor of 177Aug which has an intermediate value between those of π3s1/2 and π2d3/2 states. A similar mixed configuration is proposed for the Iπ=1/2+ ground state of 179Au. This mixing may provide evidence for triaxial shapes in the ground states in these nuclei

Change in structure between the I = 1/2 states in 181Tl and 177,179Au

© 2018 The Authors The first accurate measurements of the α-decay branching ratio and half-life of the Iπ=1/2+ ground state in 181Tl have been made, along with the first determination of the magnetic moments and I=1/2 spin assignments of the ground states in 177,179Au. The results are discussed within the complementary systematics of the reduced α-decay widths and nuclear g factors of low-lying, Iπ=1/2+ states in the neutron-deficient lead region. The findings shed light on the unexpected hindrance of the 1/2+→1/2+, 181Tl→g177Aug α decay, which is explained by a mixing of π3s1/2 and π2d3/2 configurations in 177Aug, whilst 181Tlg remains a near-pure π3s1/2. This conclusion is inferred from the g factor of 177Aug which has an intermediate value between those of π3s1/2 and π2d3/2 states. A similar mixed configuration is proposed for the Iπ=1/2+ ground state of 179Au. This mixing may provide evidence for triaxial shapes in the ground states in these nuclei.status: publishe